

# Michael B Bolger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5742108/publications.pdf>

Version: 2024-02-01

48  
papers

3,222  
citations

218677

26  
h-index

197818

49  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2801  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 262-273.	3.3	4
2	PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5- $\alpha$ -Diphospho-glucuronosyltransferase Substrates. <i>Pharmaceutics</i> , 2021, 13, 1325.	4.5	9
3	IMI "Oral biopharmaceutics tools project" Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 156, 50-63.	4.3	27
4	A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105552.	4.0	10
5	Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 155, 55-68.	4.3	38
6	Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives. <i>Pharmaceutical Research</i> , 2020, 37, 95.	3.5	8
7	Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus <sup>®</sup> . <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 305-315.	3.3	32
8	The Irrelevance of In Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 268-278.	3.3	20
9	Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series. <i>Molecular Pharmaceutics</i> , 2018, 15, 821-830.	4.6	22
10	Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 2. Rational Bioavailability Design by Global Sensitivity Analysis To Identify Properties Affecting Bioavailability. <i>Molecular Pharmaceutics</i> , 2018, 15, 831-839.	4.6	14
11	IMI "Oral biopharmaceutics tools project" Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 610-625.	4.0	58
12	The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1808-1818.	3.3	36
13	PBPK models for the prediction of in vivo performance of oral dosage forms. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 300-321.	4.0	263
14	In vivo methods for drug absorption "Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 99-151.	4.0	226
15	Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol <sup>®</sup> ) "Application of a New "Physiologically Based" Model to Assess Absorption and Disposition. <i>AAPS Journal</i> , 2013, 15, 787-796.	4.4	16
16	In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate. <i>Molecular Pharmaceutics</i> , 2012, 9, 492-504.	4.6	45
17	Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 131-141.	4.3	35
18	Modeling of Absorption. <i>Methods in Molecular Biology</i> , 2012, 929, 313-336.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Provisional Biopharmaceutical Classification of Some Common Herbs Used in Western Medicine. <i>Molecular Pharmaceutics</i> , 2012, 9, 815-822.	4.6	44
20	Predicting the Effect of Fed-State Intestinal Contents on Drug Dissolution. <i>Pharmaceutical Research</i> , 2010, 27, 2646-2656.	3.5	20
21	Mutagenesis and Cysteine Scanning of Transmembrane Domain 10 of the Human Dipeptide Transporter. <i>Pharmaceutical Research</i> , 2009, 26, 2358-2366.	3.5	25
22	Prediction of Modified Release Pharmacokinetics and Pharmacodynamics from In Vitro, Immediate Release, and Intravenous Data. <i>AAPS Journal</i> , 2009, 11, 323-334.	4.4	75
23	Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine. <i>AAPS Journal</i> , 2009, 11, 353-363.	4.4	78
24	Application of Gastrointestinal Simulation for Extensions for Biowaivers of Highly Permeable Compounds. <i>AAPS Journal</i> , 2008, 10, 213-226.	4.4	82
25	Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 4985-5002.	3.0	127
26	In Silico Modeling of Non-Linear Drug Absorption for the P-gp Substrate Talinolol and of Consequences for the Resulting Pharmacodynamic Effect. <i>Pharmaceutical Research</i> , 2006, 23, 1712-1720.	3.5	66
27	The composite solubility versus pH profile and its role in intestinal absorption prediction. <i>AAPS PharmSci</i> , 2003, 5, 35-49.	1.3	64
28	Pressure-sensitive and -insensitive coupling in $\hat{I}^3$ -aminobutyric acid receptors. <i>Psychopharmacology</i> , 2001, 157, 401-410.	3.1	4
29	Three-dimensional structure of fibrolase, the fibrinolytic enzyme from southern copperhead venom, modeled from the x-ray structure of adamalysin II and atrolysin C. <i>AAPS PharmSci</i> , 2001, 3, 78-90.	1.3	18
30	Predicting the impact of physiological and biochemical processes on oral drug bioavailability. <i>Advanced Drug Delivery Reviews</i> , 2001, 50, S41-S67.	13.7	555
31	In vivo and in vitro hyperbaric studies in mice suggest novel sites of action for ethanol. <i>Psychopharmacology</i> , 1999, 141, 339-350.	3.1	12
32	Biopharmaceutics of transmucosal peptide and protein drug administration: role of transport mechanisms with a focus on the involvement of PepT1. <i>Journal of Controlled Release</i> , 1999, 62, 129-140.	9.9	34
33	Structure, Function, and Molecular Modeling Approaches to the Study of the Intestinal Dipeptide Transporter PepT1. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1286-1291.	3.3	105
34	Molecular Identification of a Role for Tyrosine 167 in the Function of the Human Intestinal Proton-Coupled Dipeptide Transporter (hPepT1). <i>Biochemical and Biophysical Research Communications</i> , 1998, 250, 103-107.	2.1	65
35	Synthesis and In Vitro Activity of $3\hat{I}^2$ -Substituted- $3\hat{I}^1$ -hydroxypregnan-20-ones: Allosteric Modulators of the GABA <sub>A</sub> Receptor. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 61-72.	6.4	54
36	In vitro and in vivo activity of 16,17-dehydro-epipregnanolones: 17,20-bond torsional energy analysis and D-ring conformation. <i>Pharmaceutical Research</i> , 1996, 13, 1488-1494.	3.5	9

#	ARTICLE	IF	CITATIONS
37	Computational Techniques in Macromolecular Structural Analysis. , 1995, , 433-490.		1
38	The neuroactive steroid 3 $\beta$ -hydroxy-5 $\alpha$ -pregnan-20-one is a two-component modulator of ligand binding to the GABAA receptor. European Journal of Pharmacology, 1994, 269, 157-163.	2.6	53
39	Calculations of antibody-antigen interactions: microscopic and semi-microscopic evaluation of the free energies of binding of phosphorylcholine analogs to McPC603. Protein Engineering, Design and Selection, 1992, 5, 215-228.	2.1	289
40	[2] Computer modeling of combining site structure of anti-hapten monoclonal antibodies. Methods in Enzymology, 1991, 203, 21-45.	1.0	7
41	Differential Responses of Expressed Recombinant Human $\gamma$ -Aminobutyric Acid Receptors to Neurosteroids. Journal of Neurochemistry, 1991, 57, 1818-1821.	3.9	92
42	Identification and characterization of a pregnane steroid recognition site that is functionally coupled to an expressed GABAA receptor. Neurochemical Research, 1991, 16, 347-356.	3.3	47
43	Anticonvulsant profile of the progesterone metabolite 5 $\alpha$ -pregnan-3 $\beta$ -ol-20-one. European Journal of Pharmacology, 1989, 166, 325-329.	3.5	297
44	Using molecular mimicry to produce anti-receptor antibodies. BioEssays, 1985, 3, 213-217.	2.5	6
45	Statistical moment theory in chemical kinetics. Analytical Chemistry, 1985, 57, 2145-2151.	6.5	15
46	Preparation and characterization of antisera and monoclonal antibodies to haloperdol. Immunological Investigations, 1985, 14, 523-540.	2.0	10
47	Kinetics of association between bisquaternary ammonium ligands and acetylcholinesterase. Evidence for two conformational states of the enzyme from stopped-flow measurements of fluorescence. Biochemistry, 1979, 18, 3622-3629.	2.5	19
48	Thyroxine analogs. 23. Quantitative structure-activity correlation studies of in vivo and in vitro thyromimetic activities. Journal of Medicinal Chemistry, 1977, 20, 863-880.	6.4	70